Bleb injections ward off orbital tumours

Article

Bleb injections of subconjunctival chemotherapy lower the risk of developing orbital tumours in patients with retinoblastoma.

Bleb injections of subconjunctival chemotherapy lower the risk of developing orbital tumours in patients with retinoblastoma.

Professor Brian Mohney and his team, Department of Ophthalmology, Mayo Clinic, Rochester, Minnesota, USA, completed a non-comparative interventional case series on two patients who presented with bilateral retinoblastoma.

Subconjunctival chemotherapy was administered to both patients to reduce the risk or orbital tumour seeding after intravitreal injection. The outcome measures were ocular toxicity levels and the presence or absence of viable tumour cells at the injection site.

Subconjunctival chemotherapy bleb injections before intravitreal drug delivery seem to reduce the risk of orbital tumour seeding in patients with advanced stage retinoblastoma.

The paper was recently published in the British Journal of Ophthalmology and is available by clicking here.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
© 2025 MJH Life Sciences

All rights reserved.